Bluejay Diagnostics Business Summary

```json { "business_summary": "Bluejay Diagnostics, Inc. (BJDX) is a pre-revenue medical technology company specializing in rapid, near-patient diagnostic solutions designed to improve clinical outcomes in critical care. The company’s primary business model centers on the Symphony System, a proprietary point-of-care platform that utilizes a "razor-and-blade" revenue strategy, generating income through the sale of Symphony analyzers and recurring high-margin transactions for single-use test cartridges. Its lead product candidate is an IL-6 (Interleukin-6) test for sepsis triage, which aims to provide lab-quality results in approximately 20 minutes, significantly faster than traditional central laboratory methods. As of February 2026, the company is focused on its pivotal SYMON-II clinical study, having enrolled 545 of a targeted 750 patients to support a planned FDA 510(k) submission. Bluejay competes directly with established diagnostic giants such as Abbott Laboratories, Bio-Rad Laboratories, and Becton, Dickinson and Company, as well as smaller players like Co-Diagnostics. Within this landscape, Bluejay positions itself as a specialized disruptor targeting the $1.8 billion sepsis market by filling the niche for cost-effective, ultra-rapid diagnostic triage at the patient's bedside.\n\nBluejay was co-founded in 2015 by Neil Dey and Svetlana Dey, both of whom previously established Lana Management & Business Research International (LMBRI), a consulting firm for medical product launches in the U.S. and Asia. The leadership team is currently headed by Neil Dey, who serves as President, CEO, and Director, while also acting as the company’s principal financial and accounting officer following a 2024 restructuring. Dr. Dey brings extensive pedigree in lipid membrane biochemistry and holds an MBA from the University of Cambridge. The Board of Directors is chaired by Donald R. Chase, who assumed the role in August 2025, and includes notable members such as Douglas C. Wurth, a former senior executive at J.P. Morgan Asset Management, and Fred S. Zeidman, Chairman of WoodRock & Co. The company’s institutional investor base includes Sabby Management, CVI Holdings, and Geode Capital Management, supporting its ongoing transition toward commercial-scale manufacturing and regulatory engagement." } ```